Moderna (mRNA-1273) Covid-19 Vaccine, “A Systematic Review”

  • Meisha Imam Institute of Microbiology and Molecular genetics, University of the Punjab, Lahore 54000, Pakistan.
  • Rohama Zahid School of Biological Sciences, University of the Punjab, Lahore 54000, Pakistan
  • Hafiz Muhammad Rehan Institute of Microbiology and Molecular genetics, University of the Punjab, Lahore 54000, Pakistan.
  • Sidra Abid Institute of Microbiology and Molecular genetics, University of the Punjab, Lahore 54000, Pakistan.
Keywords: Covid-19, mRNA based vaccine, Moderna (mRNA-1273), Mode of action, delta variant, Immune responses, Clinical Trials, Efficacy

Abstract

A Global pandemic, declared by WHO, caused due to a deadly virus known as a “SARS-Cov-2”, has resulted in 4.3 million deaths. Its RNA based genome and lack of proofreading ability has made this virus more prone to get the frequent mutations and results in the formation of new variants and increased pathogenicity. Scientists had been trying hard to develop the ways through which this lethal virus could be eradicated, from the day the genome of SARS CoV-2 was first reported. In order to prevent from this viral infection more than 90 vaccines were developed but few of them were approved by FDA for the human trials. Moderna Inc came up with “mRNA-1273” vaccine which was given EUA approval on 18th December, 2020 by the FDA. The vaccine is based on active mRNA, translated into spike proteins of virus, is developed by the help of nanotechnology. The clinical trials have proved an efficacy of 94.1%. Moreover, the vaccine is able to prevent disease caused by the alpha, beta, gamma and delta variant of SARS-Cov 2 in recent studies. In this review article the composition, technology, mode of action, immune responses, clinical trials and efficacy as well as the comparison of moderna vaccine with other available covid-19 vaccines has been discussed.

References

. Guo, Y. R., Cao, Q. D., Hong, Z. S., Tan, Y. Y., Chen, S. D., Jin, H. J., ... & Yan, Y. (2020).The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak–an update on the status. Military Medical Research. 2020; 7: 11. doi. org/10.1186/s40779-020-00240-0.

. Haleem, A., Javaid, M., & Vaishya, R. (2020). Effects of COVID-19 pandemic in daily life. Current medicine research and practice, 10(2), 78.

. Hussain, M., Jabeen, N., Raza, F., Shabbir, S., Baig, A. A., Amanullah, A., & Aziz, B. (2020). Structural variations in human ACE2 may influence its binding with SARS‐CoV‐ 2 spike protein. Journal of medical virology, 92(9), 1580-1586.

. Zumla, A., Chan, J. F., Azhar, E. I., Hui, D. S., & Yuen, K. Y. (2016). Coronaviruses— drug discovery and therapeutic options. Nature reviews Drug discovery, 15(5), 327-347.

. Tang, C. Y., Wang, Y., Gao, C., Smith, D. R., McElroy, J. A., Li, T., ... & Wan, X. F. (2021). Increased SAR-CoV-2 shedding associated with reduced disease severity despite continually emerging genetic variants. medRxiv.

. Chadha, J., Khullar, L., & Mittal, N. (2021). Facing the wrath of enigmatic mutations: A review on the emergence of SARS‐CoV‐2 variants amid COVID‐19 pandemic. Environmental microbiology.

. Dong, L., Hu, S., & Gao, J. (2020). Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug discoveries & therapeutics, 14(1), 58-60.

. Prompetchara, E., Ketloy, C., & Palaga, T. (2020). Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pacific journal of allergy and immunology, 38(1), 1-9.

. Porter, K. R., & Raviprakash, K. (2016). DNA vaccine delivery and improved immunogenicity. Current issues in molecular biology, 22(1), 129-138.

. Lazo, L., Valdes, I., Guillén, G., Hermida, L., & Gil, L. (2019). Aiming at the heart: The capsid protein of dengue virus as a vaccine candidate. Expert review of vaccines, 18(2), 161-173.

. Iavarone, C., O’hagan, D. T., Yu, D., Delahaye, N. F., & Ulmer, J. B. (2017). Mechanism of action of mRNA-based vaccines. Expert review of vaccines, 16(9), 871-881.

. Funk, C. D., Laferrière, C., & Ardakani, A. (2021). Target product profile analysis of COVID-19 vaccines in phase III clinical trials and beyond: an early 2021 perspective. Viruses, 13(3), 418.

. Verch, T., Trausch, J. J., & Shank-Retzlaff, M. (2018). Principles of vaccine potency assays. Bioanalysis, 10(3), 163-180.

. Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018). mRNA vaccines—a new era in vaccinology. Nature reviews Drug discovery, 17(4), 261-279.

. Jackson, N. A., Kester, K. E., Casimiro, D., Gurunathan, S., & DeRosa, F. (2020). The promise of mRNA vaccines: a biotech and industrial perspective. npj Vaccines, 5(1), 1-6.

. Schlake, T., Thess, A., Fotin-Mleczek, M., & Kallen, K. J. (2012). Developing mRNA- vaccine technologies. RNA biology, 9(11), 1319-1330.

. Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2021). The dawn of mRNA vaccines: The COVID-19 case. Journal of Controlled Release, 333, 511-520.

. Moderna (2021). About Moderna Inc company. Company history and information: MRNA science. Retrieved from https://www.modernatx.com/about-us/moderna-facts

. Nasdaq (2021). Financial reports for Moderna Inc from 2017 to 2020. Retrieved from https://www.nasdaq.com/market-activity/stocks/mrna/financials

. Nobanee, H. Financial Analysis and Performance Evaluation of Moderna.https://www.researchgate.net/profile/Haitham,Nobanee/publication/353571480_Financial_Analysis_and_Performance_Evaluation_of_Moderna/links/6103a9c91ca20f6f86ea31f6/Financial-Analysis-and-Performance- Evaluation-of-Moderna.pdf

. Banerjee, A. K., Begum, F., & Ray, U. (2020). Mutation hot spots in Spike protein of COVID-19. Preprints, 2020, 2020040281.

. Teo, S. P. (2021). Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA- 1273. Journal of Pharmacy Practice, 08971900211009650.

. Buschmann, M. D., Carrasco, M. J., Alishetty, S., Paige, M., Alameh, M. G., & Weissman, D. (2021). Nanomaterial delivery systems for mRNA vaccines. Vaccines, 9(1), 65.

. Khurana, A., Allawadhi, P., Khurana, I., Allwadhi, S., Weiskirchen, R., Banothu, A. K., ... & Bharani, K. K. (2021). Role of nanotechnology behind the success of mRNA vaccines for COVID-19. Nano Today, 38, 101142.

. Reichmuth, A. M., Oberli, M. A., Jaklenec, A., Langer, R., & Blankschtein, D. (2016). mRNA vaccine delivery using lipid nanoparticles. Therapeutic delivery, 7(5), 319-334.

. Livingston, E. H. (2021). Necessity of 2 doses of the Pfizer and Moderna COVID-19 vaccines. JAMA, 325(9), 898-898.

. Kisby, T., Yilmazer, A., & Kostarelos, K. (2021). Reasons for success and lessons learnt from nanoscale vaccines against COVID-19. Nature Nanotechnology, 1-8.

. Kim, J., Eygeris, Y., Gupta, M., & Sahay, G. (2021). Self-assembled mRNA vaccines. Advanced Drug Delivery Reviews.

. Wang, F., Kream, R. M., & Stefano, G. B. (2020). An evidence based perspective on mRNA-SARS-CoV-2 vaccine development. Medical science monitor: international medical journal of experimental and clinical research, 26, e924700-1.

. CDC (2021). Moderna COVID-19 Vaccine Overview and Safety. Retrieved from https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Moderna.html Moderna (2021). About Moderna Inc company. Company history and information: MRNA science. Retrieved from https://www.modernatx.com/about-us/moderna-facts

. Siddique, S., & Ahmed, S. (2021). COVID-19 Vaccines in Pakistan: Efficacy, Adverse Effects and Availability. Journal of Islamabad Medical & Dental College, 10(2), 125-130.

Published
2021-09-07
Section
Articles